Showing 15 posts of 97 posts found.

Eli Lilly to acquire Versanis Bio for $1.9bn

July 17, 2023
Sales and Marketing Cardiology, Eli Lilly, Versanis Bio, acquisition, cardiometabolic diseases

Eli Lilly and Versanis Bio have announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company …

Croda International acquires Solus Biotech

July 4, 2023
Business Services Croda International, Pharmacy, Solus Biotech, acquisition

Croda International has confirmed that it has successfully acquired Solus Biotech, following receipt of approval from the South Korean regulatory …


Eli Lilly to acquire Sigilon Therapeutics

June 30, 2023
Business Services Chronic Diseases, Eli Lilly, Sigilon, acquisition

Eli Lilly and Sigilon Therapeutics have announced a definitive agreement for Lilly’s acquisition of Sigilon, a biopharmaceutical company focusing on …

XOMA acquires royalty and milestone rights for NPC and pancreatic cancer assets

June 23, 2023
Sales and Marketing Cancer, Oncology, Xoma, acquisition, oncology

US-based biotechnology royalty aggregator XOMA has announced that it has gained the royalty and milestone rights for two assets from …

Eli Lilly to acquire DICE Therapeutics for immunology innovations

June 21, 2023
Business Services DICE Therapeutics, Eli Lilly, Immunology, acquisition, immunology

Eli Lilly and DICE Therapeutics have announced a definitive agreement for Lilly to acquire DICE, a biopharmaceutical company focusing on …

Oncimmune Holdings sells businesses to Freenome in £13m deal

May 22, 2023
Sales and Marketing Freenome, Oncimmune Holdings, Oncology, acquisition

UK-based life sciences and immunodiagnostics firm Oncimmune Holdings has announced that it has sold its Oncimmune Limited and Oncimmune Europe …

Sobi acquires CTI BioPharma Corporation for $1.7bn

May 10, 2023
Medical Communications CTI, acquisition, sobi

Swedish Orphan Biovitrum, aka Sobi, has announced that it had entered into a ‘plan of merger’ with CTI BioPharma Corp …

Sanofi complete acquisition of mRNA company Translate Bio

September 15, 2021
Research and Development 2021, 3.2 billion, COVID-19, Sanofi, Translate Bio, acquisition, mrna, vaccines

French pharma giants Sanofi continues its run of acquisitions in 2021 by completing the deal for Translate Bio, a Massachusetts-based …


Novartis acquires Cadent Therapeutics in potential $770 million deal

December 17, 2020
Sales and Marketing Cadent, Novartis, acquisition

Novartis has sealed an agreement with Cadent Therapeutics to acquire the firm in a deal worth up to $770 million, …


Eli Lilly scoops up gene therapy specialist Prevail Therapeutics for a potential $1.04bn

December 16, 2020
Research and Development, Sales and Marketing Eli Lilly, Prevail, acquisition

Eli Lilly has struck a deal to acquire Prevail Therapeutics in a transaction that could be valued at up to …

Bayer buys out US-based Asklepios BioPharmaceutical in potential $4bn deal

October 26, 2020
Sales and Marketing Asklepios, Bayer, acquisition, pharma

Bayer has moved to bolster its cell and gene therapy (CGT) business through the acquisition of US biotech Asklepios BioPharmaceutical …


Covis Group to acquire AMAG Pharmaceuticals in $647m deal

October 5, 2020
Sales and Marketing AMAG Pharmaceuticals, Covis group, acquisition, pharma

Luxembourg-based Covis Group is set to acquire Massachusetts-based AMAG Pharmaceuticals in a new deal worth approximately $647 million on an …


Gilead scoops up Immunomedics in deal worth $21 billion

September 14, 2020
Sales and Marketing Gilead, Immunomedics, acquisition, pharma

The Board of Directors from both companies have unanimously agreed for Gilead to acquire Immunomedics for $88 per share in …


Nestlé to acquire remaining shares in Aimmune for $2.6 billion

September 2, 2020
Research and Development, Sales and Marketing Aimmune, acquisition, nestle, pharma

Food and drink giant Nestlé has confirmed it is in motion to scoop up the remaining shares in Californian biotech …


Gilead acquires immuno-oncology firm Forty Seven in $4.9 billion deal

March 3, 2020
Manufacturing and Production, Sales and Marketing Cancer, Forty Seven, Gilead, acquisition, oncology, pharma

Gilead has revealed it is to acquire the immunology firm Forty Seven in a deal valued at $95.50 per share …

Latest content